Health authorities in England rejected a pricey CAR-T cell therapy from Novartis for adults with blood cancer, two weeks after endorsing Kymriah’s use in children and young people.

Health authorities in England agreed with Novartis to fast-track access to the Swiss drugmaker’s expensive CAR-T cell therapy Kymriah and make it available to children and young people with aggressive leukemia when other drugs have failed.